Introduction: Autosomal recessive polycystic kidney disease (ARPKD) is associated with pathogenic variants in the PKHD1 gene. Autosomal dominant polycystic kidney disease (ADPKD) is mainly associated with pathogenic variants in PKD1 or PKD2. The present study aimed to identify the clinical and genetic features of Turkish pediatric ARPKD and ADPKD patients. Methods: This multicenter, retrospective cohort study included 21 genetically confirmed ARPKD and 48 genetically confirmed ADPKD patients from 7 pediatric nephrology centers. Demographic features, clinical, and laboratory findings at presentation and during 12-month intervals were recorded. Results: The median age of the ARPKD patients at diagnosis was lower than the median age of ADPKD patients (10.5 months [range: 0–15 years] vs. 5.2 years [range: 0.1–16 years], respectively, [p = 0.014]). At the time of diagnosis, the median eGFR in the ARPKD patients was lower compared to that of ADPKD patients (81.6 [IQR: 28.7–110.5] mL/min/1.73 m2 and 118 [IQR: 91.2–139.8] mL/min/1.73 m2, respectively, [p = 0.0001]). In total, 11 (52.4%) ARPKD patients had malnutrition; 7 (33.3%) patients had growth retardation at presentation; and 4 (19%) patients had both malnutrition and growth retardation. At diagnosis, 8 (16.7%) of the ADPKD patients had malnutrition, and 5 (10.4%) patients had growth retardation. The malnutrition, growth retardation, and hypertension rates at diagnosis were higher in the ARPKD patients than the ADPKD patients (p = 0.002, p = 0.02, and p = 0.0001, respectively). ARPKD patients with malnutrition and growth retardation had worse renal survival compared to the patients without (p = 0.03 and p = 0.01). Similarly, ADPKD patients with malnutrition had worse renal survival compared to the patients without (p = 0.002). ARPKD patients with truncating variants had poorer 3- and 6-year renal outcome than those carrying non-truncating variants (p = 0.017). Conclusion: Based on renal survival analysis, type of genetic variant, growth retardation, and/or malnutrition at presentation were observed to be factors associated with progression to chronic kidney disease (CKD). Differentiation of ARPKD and ADPKD, and identification of the predictors of the development of CKD are vital for optimal management of patients with ARPKD or ADPKD.

Keywords:
Autosomal dominant polycystic kidney disease, Autosomal recessive polycystic kidney disease, Chronic kidney disease, <italic>PKD1</italic>, <italic>PKD2</italic>, <italic>PKHD1</italic>, Prognosis
1.
Patil A, Sweeney WE Jr, Avner ED, Pan C. Childhood polycystic kidney disease. In: Li X, editor. Polycystic kidney disease. Brisbane (AU): Codon Publications Copyright The Authors; 2015. p. 22–4. [Chapter 2].
2.
Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014 Sep;134(3):e833–45.
https://doi.org/10.1542/peds.2013-3646
3.
Sweeney WE, Avner ED. Polycystic kidney disease, autosomal recessive. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al. , editors. Gene Reviews(®). Seattle (WA)Seattle Copyright ©: University of Washington; 1993-2020. p. 6–8.
4.
Sweeney WE, Jr, Avner ED. Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol. 2011 May;26(5):675–92.
https://doi.org/10.1007/s00467-010-1656-1
5.
Burgmaier K, Brinker L, Erger F, Beck BB, Benz MR, Bergmann C, et al. Refining genotype-phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants. Kidney Int. 2021 Sep;100(3):650–9.
https://doi.org/10.1016/j.kint.2021.04.019
6.
Denamur E, Delezoide AL, Alberti C, Bourillon A, Gubler MC, Bouvier R, et al. Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease. Kidney Int. 2010 Feb;77(4):350–8.
https://doi.org/10.1038/ki.2009.440
7.
Geme RMKJS. Chapter 57: Measurement of Undernutrition. Nelson textbook of pediatrics. 21th ed. 2020. Table 57.2.
8.
Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc. 2009 Nov;4(11):1832–43.
https://doi.org/10.2215/cjn.01640309
9.
Mastrangelo A, Paglialonga F, Edefonti A. Assessment of nutritional status in children with chronic kidney disease and on dialysis. Pediatr Nephrol. 2014 Aug;29(8):1349–58.
https://doi.org/10.1007/s00467-013-2612-7
10.
Warady BA, Alexander SR, Watkins S, Kohaut E, Harmon WE. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis. 1999 Mar;33(3):567–83.
https://doi.org/10.1016/s0272-6386(99)70196-4
11.
Zerres K, Rudnik-Schöneborn S, Deget F, Holtkamp U, Brodehl J, Geisert J, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft für Pädiatrische, Nephrologie. Acta Paediatr. 1996 Apr;85(4):437–45.
https://doi.org/10.1111/j.1651-2227.1996.tb14056.x
12.
Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003 May;111(5 Pt 1):1072–80.
https://doi.org/10.1542/peds.111.5.1072
13.
Hartung EA, Dell KM, Matheson M, Warady BA, Furth SL. Growth in children with autosomal recessive polycystic kidney disease in the CKiD cohort study. Front Pediatr. 2016 Aug 10;4:82.
https://doi.org/10.3389/fped.2016.00082
14.
Burgmaier K, Brandt J, Shroff R, Witters P, Weber LT, Dötsch J, et al. Gastrostomy tube insertion in pediatric patients with autosomal recessive polycystic kidney disease (ARPKD): current practice. Front Pediatr. 2018 Jun 4;6:164.
https://doi.org/10.3389/fped.2018.00164
15.
Serra R. Role of intraflagellar transport and primary cilia in skeletal development. Anat Rec. 2008 Sep;291(9):1049–61.
https://doi.org/10.1002/ar.20634
16.
Beaunoyer M, Snehal M, Li L, Concepcion W, Salvatierra O Jr, Sarwal M. Optimizing outcomes for neonatal ARPKD. Pediatr Transpl. 2007 May;11(3):267–71.
https://doi.org/10.1111/j.1399-3046.2006.00644.x
17.
Hamo S, Bacchetta J, Bertholet-Thomas A, Ranchin B, Cochat P, Michel-Calemard L. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD): genotype-phenotype correlations from a series of 308 cases to improve prenatal counselling. Nephrol Ther. 2018 Nov;14(6):474–7.
https://doi.org/10.1016/j.nephro.2018.03.002
18.
Keith DS, Torres VE, Johnson CM, Holley KE. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis. 1994 Sep;24(3):491–8.
https://doi.org/10.1016/s0272-6386(12)80907-3
19.
Tomobe K, Philbrick D, Aukema HM, Clark WF, Ogborn MR, Parbtani A, et al. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol. 1994 Dec;5(6):1355–60.
https://doi.org/10.1681/ASN.V561355
20.
Taylor JM, Hamilton-Reeves JM, Sullivan DK, Gibson CA, Creed C, Carlson SE, et al. Diet and polycystic kidney disease: a pilot intervention study. Clin Nutr. 2017 Apr;36(2):458–66.
https://doi.org/10.1016/j.clnu.2016.01.003
21.
Amro OW, Paulus JK, Noubary F, Perrone RD. Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. Am J Kidney Dis. 2016 Dec;68(6):882–91.
https://doi.org/10.1053/j.ajkd.2016.07.023
22.
Maditz KH, Gigliotti JC, Tou JC. Evidence for a role of proteins, lipids, and phytochemicals in the prevention of polycystic kidney disease progression and severity. Nutr Rev. 2013 Dec;71(12):802–14.
https://doi.org/10.1111/nure.12085
23.
Di Iorio BR, Cupisti A, D’Alessandro C, Bellasi A, Barbera V, Di Lullo L. Nutritional therapy in autosomal dominant polycystic kidney disease. J Nephrol. 2018 Oct;31(5):635–43.
https://doi.org/10.1007/s40620-018-0470-x
24.
Ryu H, Kim H, Park HC, Kim H, Cho EJ, Lee KB, et al. Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2017 Jan;18(1):22.
https://doi.org/10.1186/s12882-016-0434-0
25.
Aukema HM, Ogborn MR, Tomobe K, Takahashi H, Hibino T, Holub BJ. Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease. Kidney Int. 1992 Oct;42(4):837–42.
https://doi.org/10.1038/ki.1992.358
26.
Evenepoel P, Claes K, Cavalier E, Meijers B, Stenvinkel P, Behets G, et al. A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney Int. 2019 Feb;95(2):412–9.
https://doi.org/10.1016/j.kint.2018.09.018
27.
Xiao Z, Zhang S, Magenheimer BS, Luo J, Quarles LD. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem. 2008 May 2;283(18):12624–34.
https://doi.org/10.1074/jbc.M710407200
28.
Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013 May;24(6):1006–13.
https://doi.org/10.1681/ASN.2012070650
29.
Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, et al. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J Am Soc Nephrol. 2010 Sep;21(9):1510–20.
https://doi.org/10.1681/ASN.2010030237
30.
Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int. 2004 Dec;66(6):2132–6.
https://doi.org/10.1111/j.1523-1755.2004.66003.x
31.
Furu L, Onuchic LF, Gharavi A, Hou X, Esquivel EL, Nagasawa Y, et al. Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol. 2003 Aug;14(8):2004–14.
https://doi.org/10.1097/01.asn.0000078805.87038.05
32.
Bergmann C, von Bothmer J, Ortiz Brüchle N, Venghaus A, Frank V, Fehrenbach H, et al. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol. 2011 Nov;22(11):2047–56.
https://doi.org/10.1681/ASN.2010101080
33.
Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, et al. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 Feb;97(2):370–82.
https://doi.org/10.1016/j.kint.2019.08.038
34.
Lanktree MB, Guiard E, Li W, Akbari P, Haghighi A, Iliuta IA, et al. Intrafamilial variability of ADPKD. Kidney Int Rep. 2019 May 7;4(7):995–1003.
https://doi.org/10.1016/j.ekir.2019.04.018
35.
Lanktree MB, Iliuta IA, Haghighi A, Song X, Pei Y. Evolving role of genetic testing for the clinical management of autosomal dominant polycystic kidney disease. Nephrol Dial Transpl. 2019 Sep 1;34(9):1453–60.
https://doi.org/10.1093/ndt/gfy261
36.
Al-Hamed MH, Alsahan N, Rice SJ, Edwards N, Nooreddeen E, Alotaibi M, et al. Bialleleic PKD1 mutations underlie early-onset autosomal dominant polycystic kidney disease in Saudi Arabian families. Pediatr Nephrol. 2019 Sep;34(9):1615–23.
https://doi.org/10.1007/s00467-019-04267-x
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.